Kuldev Singh, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Singh’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A50924 · Current
Licensed to practise in California · since 1992 · expires 2028-02-29 · Johns Hopkins University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$147,169
Medicare paid this office $147,169 for 435 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 406 | $88,513 | $77 |
| Removal of cataract with insertion of prosthetic lens | 20 | $13,019 | $482 |
| Exam of visual field with extended testing | 326 | $8,827 | $23 |
| Short return visit (20+ min) | 49 | $4,294 | $51 |
| Removal of recurring cataract in lens capsule using a laser | 11 | $3,515 | $293 |
See all 10 services
| Return visit (30+ min) | 406 | $88,513 | $77 |
| Removal of cataract with insertion of prosthetic lens | 20 | $13,019 | $482 |
| Exam of visual field with extended testing | 326 | $8,827 | $23 |
| Short return visit (20+ min) | 49 | $4,294 | $51 |
| Removal of recurring cataract in lens capsule using a laser | 11 | $3,515 | $293 |
| New patient visit (45+ min) | 17 | $1,923 | $113 |
| Short return visit | 18 | $1,074 | $28 |
| Measurement of corneal curvature and depth of eye | 20 | $523 | $26 |
| Exam of the internal drainage system of eye | 17 | $324 | $19 |
| Ultrasound scan of cornea to determine thickness | 13 | $90 | $7 |
Procedures Medicare counted
| Cataract surgery | 39 | More than 59% of doctors who do this |
Who their Medicare patients are
435 Original Medicare patients in 2024. Average age 79 · Women 54% · Also on Medicaid 19% · Health risk score 1.03. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 65% · Coronary heart disease 25% · Diabetes 24% · Atrial fibrillation 19% · Chronic kidney disease 17% · Cancer 15% · Depression 12% · Heart failure 11% · COPD 8% · Stroke 6% · Dementia 5%.
The office billed $602,761, Medicare allowed $204,476 and paid $147,169; for 1,819 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 435 | 1,819 | 79 | 1.03 | $602,761 | $147,169 |
| 2023 | 440 | 1,800 | 79 | 1.08 | $710,384 | $163,050 |
| 2022 | 467 | 1,877 | 79 | 1.04 | $618,133 | $145,901 |
| 2021 | 470 | 1,879 | 79 | 1.08 | $575,618 | $143,955 |
| 2020 | 479 | 1,641 | 78 | 1.14 | $435,377 | $88,471 |
| 2019 | 568 | 2,181 | 78 | 1.16 | $777,431 | $142,909 |
| 2018 | 624 | 2,379 | 78 | 1.16 | $949,076 | $164,255 |
| 2017 | 630 | 2,482 | 77 | 1.19 | $973,900 | $166,965 |
| 2016 | 647 | 2,572 | 77 | 1.12 | $1,271,615 | $207,848 |
| 2015 | 644 | 2,577 | 77 | 1.15 | $1,125,602 | $194,212 |
| 2014 | 618 | 2,603 | 77 | 1.06 | $1,077,280 | $190,347 |
| 2013 | 586 | 2,452 | 77 | 1.09 | $875,582 | $168,351 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 403 | $82,206 | $80 |
| Creation of eye fluid drainage tract for treatment of glaucoma | 16 | $18,448 | $1,085 |
| Removal of cataract with insertion of prosthetic lens | 24 | $15,233 | $462 |
| Short return visit (20+ min) | 100 | $9,104 | $55 |
| Exam of visual field with extended testing | 306 | $9,028 | $24 |
| New patient visit (45+ min) | 15 | $1,315 | $88 |
| Short return visit | 20 | $1,164 | $30 |
| Measurement of corneal curvature and depth of eye | 28 | $774 | $28 |
| Exam of the internal drainage system of eye | 20 | $353 | $18 |
| Ultrasound scan of cornea to determine thickness | 17 | $110 | $6 |
2022: 9 services
| Return visit (30+ min) | 410 | $73,744 | $77 |
| Removal of cataract with insertion of prosthetic lens | 28 | $17,736 | $479 |
| Short return visit (20+ min) | 172 | $14,392 | $48 |
| Exam of visual field with extended testing | 334 | $8,676 | $21 |
| New patient visit (45+ min) | 17 | $1,686 | $99 |
| Short return visit | 16 | $946 | $26 |
| Measurement of corneal curvature and depth of eye | 26 | $670 | $26 |
| Exam of the internal drainage system of eye | 18 | $329 | $18 |
| Ultrasound scan of cornea to determine thickness | 15 | $104 | $7 |
2021: 10 services
| Return visit (30+ min) | 400 | $61,125 | $76 |
| Short return visit (20+ min) | 244 | $23,460 | $54 |
| Creation of eye fluid drainage tract for treatment of glaucoma | 13 | $13,565 | $1,043 |
| Removal of cataract with insertion of prosthetic lens | 20 | $12,395 | $477 |
| Exam of visual field with extended testing | 352 | $9,952 | $22 |
| New patient visit (45+ min) | 24 | $2,777 | $116 |
| Measurement of corneal curvature and depth of eye | 24 | $742 | $30 |
| Exam of the internal drainage system of eye | 22 | $404 | $18 |
| Imaging of optic nerve | 15 | $253 | $17 |
| Ultrasound scan of cornea to determine thickness | 17 | $110 | $6 |
2020: 8 services
| Established patient problem focused exam of visual system | 405 | $36,910 | $42 |
| Established patient complete exam of visual system | 215 | $14,365 | $65 |
| Exam of visual field with extended testing | 329 | $9,432 | $24 |
| Removal of cataract with insertion of prosthetic lens | 13 | $8,722 | $513 |
| Measurement of corneal curvature and depth of eye | 15 | $363 | $24 |
| Imaging of optic nerve | 20 | $324 | $16 |
| Exam of the internal drainage system of eye | 16 | $235 | $15 |
| Ultrasound scan of cornea to determine thickness | 11 | $70 | $6 |
2019: 11 services
| Established patient problem focused exam of visual system | 481 | $49,982 | $44 |
| Established patient complete exam of visual system | 296 | $20,994 | $67 |
| Removal of cataract with insertion of prosthetic lens | 23 | $14,591 | $561 |
| Creation of eye fluid drainage tract for treatment of glaucoma with previous scarring | 12 | $13,699 | $1,142 |
| Exam of visual field with extended testing | 392 | $11,460 | $24 |
| Return visit (30+ min) | 20 | $1,308 | $62 |
| New patient visit (30+ min) | 18 | $1,151 | $64 |
| Measurement of corneal curvature and depth of eye | 28 | $762 | $26 |
| Imaging of optic nerve | 35 | $674 | $19 |
| Exam of the internal drainage system of eye | 38 | $604 | $15 |
| Ultrasound scan of cornea to determine thickness | 29 | $170 | $6 |
2018: 12 services
| Established patient problem focused exam of visual system | 501 | $51,195 | $44 |
| Creation of eye fluid drainage tract for treatment of glaucoma with previous scarring | 19 | $25,850 | $1,124 |
| Established patient complete exam of visual system | 347 | $23,470 | $64 |
| Removal of cataract with insertion of prosthetic lens | 30 | $19,533 | $558 |
| Exam of visual field with extended testing | 411 | $11,697 | $24 |
| Removal of recurring cataract in lens capsule using a laser | 12 | $3,791 | $292 |
| New patient visit (30+ min) | 51 | $3,140 | $62 |
| Return visit (30+ min) | 28 | $1,602 | $57 |
| Exam of the internal drainage system of eye | 68 | $1,247 | $18 |
| Imaging of optic nerve | 30 | $577 | $19 |
| Measurement of corneal curvature and depth of eye | 22 | $563 | $26 |
| Ultrasound scan of cornea to determine thickness | 52 | $429 | $8 |
2017: 12 services
| Established patient problem focused exam of visual system | 506 | $52,501 | $43 |
| Removal of cataract with insertion of prosthetic lens | 38 | $28,007 | $560 |
| Established patient complete exam of visual system | 357 | $24,201 | $65 |
| Creation of eye fluid drainage tract for treatment of glaucoma with previous scarring | 15 | $17,150 | $1,143 |
| Exam of visual field with extended testing | 416 | $12,010 | $24 |
| New patient visit (30+ min) | 43 | $2,501 | $58 |
| Return visit (30+ min) | 31 | $2,066 | $67 |
| Exam of the internal drainage system of eye | 71 | $1,286 | $18 |
| Measurement of corneal curvature and depth of eye | 33 | $935 | $28 |
| Imaging of optic nerve | 23 | $421 | $18 |
| Ultrasound scan of cornea to determine thickness | 51 | $419 | $8 |
| Photography of the retina | 13 | $244 | $19 |
2016: 14 services
| Established patient problem focused exam of visual system | 514 | $51,748 | $44 |
| Removal of cataract with insertion of prosthetic lens | 64 | $48,810 | $581 |
| Established patient complete exam of visual system | 333 | $22,393 | $64 |
| Creation of eye fluid drainage tract for treatment of glaucoma with previous scarring | 14 | $20,317 | $1,195 |
| Creation of eye fluid drainage tract for treatment of glaucoma | 14 | $13,095 | $935 |
| Exam of visual field with extended testing | 416 | $11,750 | $24 |
| New patient visit (30+ min) | 84 | $4,780 | $57 |
| Removal of recurring cataract in lens capsule using a laser | 13 | $3,792 | $292 |
| Exam of the internal drainage system of eye | 98 | $1,722 | $17 |
| Return visit (30+ min) | 18 | $1,051 | $58 |
| New patient complete exam of visual system | 12 | $1,007 | $84 |
| Measurement of corneal curvature and depth of eye | 33 | $902 | $27 |
| Ultrasound scan of cornea to determine thickness | 81 | $663 | $8 |
| Imaging of optic nerve | 16 | $390 | $24 |
2015: 12 services
| Established patient problem focused exam of visual system | 495 | $55,958 | $43 |
| Removal of cataract with insertion of prosthetic lens | 57 | $40,525 | $540 |
| Established patient complete exam of visual system | 332 | $22,640 | $65 |
| Creation of eye fluid drainage tract for treatment of glaucoma | 13 | $16,059 | $1,147 |
| Exam of visual field with extended testing | 395 | $11,300 | $24 |
| New patient visit (30+ min) | 68 | $4,041 | $59 |
| Exam of the internal drainage system of eye | 82 | $1,473 | $18 |
| Return visit (30+ min) | 17 | $1,053 | $62 |
| Measurement of corneal curvature and depth of eye | 20 | $554 | $28 |
| Ultrasound scan of cornea to determine thickness | 63 | $528 | $8 |
| Photography of the retina | 15 | $334 | $22 |
| Imaging of optic nerve | 12 | $312 | $26 |
2014: 12 services
| Established patient problem focused exam of visual system | 494 | $53,409 | $44 |
| Removal of cataract with insertion of prosthetic lens | 54 | $38,365 | $556 |
| Established patient complete exam of visual system | 348 | $24,008 | $65 |
| Creation of eye fluid drainage tract for treatment of glaucoma with previous scarring | 12 | $18,942 | $1,457 |
| Exam of visual field with extended testing | 401 | $13,994 | $24 |
| Creation of eye fluid drainage tract for treatment of glaucoma | 12 | $13,839 | $1,153 |
| New patient visit (30+ min) | 89 | $5,288 | $59 |
| Exam of the internal drainage system of eye | 86 | $1,594 | $18 |
| Return visit (30+ min) | 11 | $769 | $70 |
| Measurement of corneal curvature and depth of eye | 20 | $558 | $28 |
| Ultrasound scan of cornea to determine thickness | 54 | $444 | $8 |
| Photography of the retina | 14 | $276 | $20 |
2013: 11 services
| Established patient problem focused exam of visual system | 478 | $54,467 | $43 |
| Removal of cataract with insertion of prosthetic lens | 37 | $26,437 | $601 |
| Established patient complete exam of visual system | 371 | $25,109 | $64 |
| Creation of eye fluid drainage tract for treatment of glaucoma with previous scarring | 14 | $21,911 | $1,461 |
| Exam of visual field with extended testing | 391 | $11,949 | $24 |
| Laser repair to improve eye fluid flow | 11 | $3,252 | $271 |
| New patient visit (30+ min) | 34 | $2,074 | $61 |
| Return visit (30+ min) | 20 | $1,153 | $58 |
| Exam of the internal drainage system of eye | 57 | $1,040 | $18 |
| Measurement of corneal curvature and depth of eye | 21 | $601 | $29 |
| Ultrasound scan of cornea to determine thickness | 42 | $345 | $8 |
Medicaid work
$4,163 in 2024
Medicaid paid $4,163 for 119 billed services this clinician did in 2024, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 119 | $4,163 |
| 2024 | 119 | 1 | 21 | $4,163 |
| 2023 | 216 | 1 | 27 | $4,397 |
| 2022 | 167 | 1 | 22 | $2,911 |
| 2021 | 138 | 1 | 22 | $2,497 |
| 2020 | 115 | 1 | 26 | $2,813 |
| 2019 | 225 | 2 | 28 | $3,194 |
| 2018 | 328 | 3 | 34 | $5,030 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 216 | $4,397 |
2022
| Return visit (30+ min) | 167 | $2,911 |
2021
| Return visit (30+ min) | 138 | $2,497 |
2020
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 115 | $2,813 |
2019
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 209 | $3,122 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 16 | $72 |
2018
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 251 | $4,250 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 46 | $415 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 31 | $365 |
Drugs they prescribed that Part D paid
$50,097
Pharmacies billed $50,097 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 434) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
191 generic and 243 brand-name prescriptions · $50,097 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rhopressa | 14 | $9,580 | $684 |
| Lumigan | 24 | $8,916 | $372 |
| Alphagan P | 17 | $7,285 | $429 |
| Cyclosporine | 21 | $3,673 | $175 |
| Brinzolamide | 20 | $3,047 | $152 |
See all 11 drugs
| Rhopressa | 14 | $9,580 | $684 |
| Lumigan | 24 | $8,916 | $372 |
| Alphagan P | 17 | $7,285 | $429 |
| Cyclosporine | 21 | $3,673 | $175 |
| Brinzolamide | 20 | $3,047 | $152 |
| Latanoprost | 142 | $1,335 | $9 |
| Brimonidine | 15 | $1,107 | $74 |
| Dorzolamide-Timolol | 43 | $655 | $15 |
| Prednisolone Acetate | 15 | $635 | $42 |
| Timolol Maleate | 39 | $597 | $15 |
| Dorzolamide | 33 | $469 | $14 |
Year by year
| 2024 | 434 | 124 | 0% (0) | 56% | $50,097 |
| 2023 | 326 | 115 | 0% (0) | 50% | $48,599 |
| 2022 | 465 | 141 | 0% (0) | 55% | $89,206 |
| 2021 | 604 | 174 | 0% (0) | 60% | $117,704 |
| 2020 | 487 | 132 | 0% (0) | 49% | $60,995 |
| 2019 | 488 | 160 | 0% (0) | 49% | $59,967 |
| 2018 | 458 | 155 | 0% (0) | 55% | $59,071 |
| 2017 | 478 | 184 | None | 47% | $43,920 |
| 2016 | 515 | 174 | 0% (0) | 54% | $58,623 |
| 2015 | 662 | 190 | 0% (0) | 59% | $66,360 |
| 2014 | 651 | 184 | 0% (0) | 57% | $55,310 |
| 2013 | 743 | 192 | 0% (0) | 64% | $61,206 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Vyzulta | 16 | $5,612 | $351 |
| Brinzolamide | 19 | $5,199 | $274 |
| Travoprost | 14 | $2,496 | $178 |
| Latanoprost | 97 | $1,681 | $17 |
| Brimonidine | 14 | $1,324 | $95 |
| Prednisolone Acetate | 18 | $909 | $51 |
| Dorzolamide-Timolol | 36 | $885 | $25 |
| Dorzolamide | 17 | $387 | $23 |
| Timolol Maleate | 26 | $384 | $15 |
2022: 14 drugs
| Azopt | 27 | $12,465 | $462 |
| Alphagan P | 12 | $12,239 | $1,020 |
| Lumigan | 22 | $11,501 | $523 |
| Vyzulta | 21 | $5,941 | $283 |
| Brinzolamide | 15 | $4,960 | $331 |
| Simbrinza | 24 | $4,902 | $204 |
| Travoprost | 20 | $4,433 | $222 |
| Latanoprost | 106 | $2,670 | $25 |
| Brimonidine | 21 | $2,114 | $101 |
| Dorzolamide-Timolol | 12 | $1,939 | $162 |
| Dorzolamide-Timolol | 48 | $1,014 | $21 |
| Prednisolone Acetate | 15 | $679 | $45 |
| Timolol Maleate | 35 | $419 | $12 |
| Dorzolamide | 21 | $303 | $14 |
2021: 16 drugs
| Azopt | 30 | $15,346 | $512 |
| Alphagan P | 19 | $12,532 | $660 |
| Restasis | 14 | $9,097 | $650 |
| Lumigan | 20 | $9,045 | $452 |
| Travoprost | 25 | $7,612 | $304 |
| Combigan | 17 | $6,593 | $388 |
| Zioptan | 14 | $5,760 | $411 |
| Vyzulta | 11 | $4,194 | $381 |
| Simbrinza | 22 | $4,181 | $190 |
| Brimonidine | 50 | $3,585 | $72 |
| Durezol | 16 | $3,301 | $206 |
| Latanoprost | 134 | $3,134 | $23 |
| Dorzolamide-Timolol | 59 | $2,874 | $49 |
| Prednisolone Acetate | 21 | $1,305 | $62 |
| Dorzolamide | 26 | $788 | $30 |
| Timolol Maleate | 37 | $419 | $11 |
2020: 9 drugs
| Azopt | 37 | $17,122 | $463 |
| Durezol | 18 | $4,250 | $236 |
| Brimonidine | 45 | $4,056 | $90 |
| Vyzulta | 11 | $3,954 | $359 |
| Simbrinza | 20 | $3,443 | $172 |
| Dorzolamide-Timolol | 57 | $2,921 | $51 |
| Latanoprost | 139 | $2,493 | $18 |
| Dorzolamide | 26 | $863 | $33 |
| Timolol Maleate | 48 | $648 | $13 |
2019: 12 drugs
| Azopt | 35 | $18,354 | $524 |
| Lumigan | 14 | $5,555 | $397 |
| Durezol | 23 | $4,892 | $213 |
| Travatan Z | 16 | $4,133 | $258 |
| Zioptan | 17 | $3,952 | $232 |
| Dorzolamide-Timolol | 41 | $3,001 | $73 |
| Latanoprost | 140 | $2,738 | $20 |
| Prednisolone Acetate | 35 | $1,615 | $46 |
| Brimonidine | 26 | $1,223 | $47 |
| Acetazolamide Er | 18 | $1,049 | $58 |
| Dorzolamide | 20 | $485 | $24 |
| Timolol Maleate | 46 | $445 | $10 |
2018: 11 drugs
| Azopt | 26 | $9,628 | $370 |
| Lumigan | 22 | $8,069 | $367 |
| Travatan Z | 22 | $5,838 | $265 |
| Combigan | 24 | $5,525 | $230 |
| Simbrinza | 14 | $3,267 | $233 |
| Latanoprost | 142 | $2,789 | $20 |
| Pilocarpine | 22 | $1,655 | $75 |
| Brimonidine | 16 | $1,387 | $87 |
| Prednisolone Acetate | 23 | $1,184 | $51 |
| Dorzolamide-Timolol | 36 | $798 | $22 |
| Timolol Maleate | 34 | $474 | $14 |
2017: 12 drugs
| Azopt | 19 | $7,870 | $414 |
| Lumigan | 12 | $3,796 | $316 |
| Travatan Z | 16 | $3,760 | $235 |
| Combigan | 16 | $3,326 | $208 |
| Latanoprost | 160 | $3,323 | $21 |
| Durezol | 15 | $2,470 | $165 |
| Brimonidine | 33 | $1,997 | $61 |
| Prednisolone Acetate | 35 | $1,954 | $56 |
| Simbrinza | 13 | $1,850 | $142 |
| Dorzolamide-Timolol | 52 | $1,367 | $26 |
| Timolol Maleate | 37 | $710 | $19 |
| Dorzolamide | 20 | $431 | $22 |
2016: 11 drugs
| Azopt | 23 | $8,988 | $391 |
| Brimonidine | 48 | $8,434 | $176 |
| Lumigan | 26 | $7,931 | $305 |
| Travatan Z | 26 | $5,654 | $217 |
| Risperidone | 16 | $3,719 | $232 |
| Durezol | 19 | $3,105 | $163 |
| Prednisolone Acetate | 41 | $2,583 | $63 |
| Latanoprost | 133 | $2,424 | $18 |
| Dorzolamide-Timolol | 42 | $969 | $23 |
| Dorzolamide | 24 | $630 | $26 |
| Timolol Maleate | 35 | $336 | $10 |
2015: 16 drugs
| Azopt | 38 | $8,987 | $237 |
| Alphagan P | 24 | $6,628 | $276 |
| Lumigan | 35 | $6,538 | $187 |
| Travatan Z | 24 | $5,432 | $226 |
| Brimonidine | 34 | $4,551 | $134 |
| Durezol | 22 | $3,503 | $159 |
| Risperidone | 12 | $2,922 | $243 |
| Prednisolone Acetate | 41 | $2,866 | $70 |
| Latanoprost | 170 | $2,771 | $16 |
| Simbrinza | 19 | $2,416 | $127 |
| Vigamox | 11 | $1,757 | $160 |
| Zioptan | 11 | $1,626 | $148 |
| Pilocarpine | 22 | $1,500 | $68 |
| Dorzolamide-Timolol | 59 | $1,327 | $22 |
| Timolol Maleate | 49 | $497 | $10 |
| Dorzolamide | 15 | $371 | $25 |
2014: 13 drugs
| Alphagan P | 34 | $7,801 | $229 |
| Lumigan | 34 | $6,599 | $194 |
| Durezol | 36 | $4,762 | $132 |
| Travatan Z | 28 | $4,485 | $160 |
| Azopt | 26 | $4,362 | $168 |
| Brimonidine | 45 | $3,183 | $71 |
| Latanoprost | 150 | $2,967 | $20 |
| Prednisolone Acetate | 44 | $2,871 | $65 |
| Combigan | 19 | $2,352 | $124 |
| Dorzolamide-Timolol | 69 | $2,000 | $29 |
| Simbrinza | 11 | $1,418 | $129 |
| Acetazolamide | 13 | $838 | $64 |
| Timolol Maleate | 63 | $599 | $10 |
2013: 15 drugs
| Azopt | 61 | $9,330 | $153 |
| Lumigan | 54 | $8,769 | $162 |
| Travatan Z | 50 | $8,326 | $167 |
| Alphagan P | 46 | $7,875 | $171 |
| Latanoprost | 176 | $4,014 | $23 |
| Brimonidine | 41 | $3,163 | $77 |
| Durezol | 23 | $2,559 | $111 |
| Combigan | 19 | $2,529 | $133 |
| Xalatan | 14 | $2,479 | $177 |
| Dorzolamide-Timolol | 50 | $2,020 | $40 |
| Vigamox | 16 | $2,010 | $126 |
| Simbrinza | 11 | $1,092 | $99 |
| Prednisolone Acetate | 43 | $769 | $18 |
| Timolol Maleate | 75 | $721 | $10 |
| Dorzolamide | 14 | $398 | $28 |
Money from drug and device companies
$130,684 in 2025
| 2025 | 8 | 35 | $127,524 | $130,684 |
| 2024 | 5 | 22 | $61,100 | $62,320 |
| 2023 | 10 | 43 | $236,687 | $237,803 |
| 2022 | 9 | 64 | $201,264 | $375,190 |
| 2021 | 7 | 36 | $183,535 | $211,183 |
| 2020 | 7 | 45 | $151,874 | $218,024 |
| 2019 | 9 | 85 | $163,148 | $251,677 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Apellis Pharmaceuticals | Syfovre | $50,899 | 7 payments
|
| Bausch & Lomb Americas | Envista Envy Iol | $33,597 | 6 payments
|
| Sight Sciences | Omni Surgical System | $32,102 | 9 payments
|
| W. L. Gore & Associates | Product in Development | $12,750 | 1 payment
|
| Alcon Vision | Hydrus Microstent | $856 | 8 payments
|
| Abbvie | Durysta | $276 | 2 payments
|
See all 35 published payments
| Apellis Pharmaceuticals | Consulting · 2025-12-05 | Syfovre | $7,848 |
| W. L. Gore & Associates | Consulting · 2025-11-21 | Product in Development | $12,750 |
| Alcon Vision | Meals · 2025-11-12 | Rocklatan | $37 |
| Sight Sciences | Meals · 2025-11-04 | Omni Surgical System | $110 |
| Apellis Pharmaceuticals | Consulting · 2025-10-31 | Syfovre | $6,867 |
| Bausch & Lomb Americas | Consulting · 2025-10-28 | None | $7,500 |
| Apellis Pharmaceuticals | Consulting · 2025-10-24 | Syfovre | $5,886 |
| Sight Sciences | Meals · 2025-10-19 | Omni Surgical System | $98 |
| Sight Sciences | Travel · 2025-10-16 | Omni Surgical System | $1,130 |
| Sight Sciences | Paid to speak or teach · 2025-10-16 | Omni Surgical System | $6,750 |
| Sight Sciences | Paid to speak or teach · 2025-10-16 | Omni Surgical System | $13,500 |
| Alcon Vision | Meals · 2025-09-17 | Hydrus Microstent | $52 |
| Abbvie | Meals · 2025-09-10 | Lumigan | $126 |
| Bausch & Lomb Americas | Consulting · 2025-07-15 | None | $9,375 |
| Apellis Pharmaceuticals | Consulting · 2025-07-03 | Syfovre | $5,640 |
| Alcon Vision | Meals · 2025-06-25 | Hydrus Microstent | $153 |
| Tarsus Pharmaceuticals | Meals · 2025-06-05 | None | $55 |
| Apellis Pharmaceuticals | Consulting · 2025-05-22 | Syfovre | $5,886 |
| Abbvie | Meals · 2025-05-07 | Durysta | $150 |
| Sight Sciences | Meals · 2025-04-26 | Omni Surgical System | $139 |
| Alcon Vision | Meals · 2025-04-25 | None | $119 |
| Bausch & Lomb Americas | Meals · 2025-04-25 | None | $105 |
| Sight Sciences | Paid to speak or teach · 2025-04-17 | Omni Surgical System | $5,750 |
| Alcon Vision | Meals · 2025-04-14 | Constellation | $150 |
| Apellis Pharmaceuticals | Consulting · 2025-04-14 | Syfovre | $11,772 |
| Bausch & Lomb Americas | Consulting · 2025-04-04 | None | $9,000 |
| Bausch & Lomb Americas | Meals · 2025-03-19 | Envista Envy Iol | $117 |
| Alcon Vision | Meals · 2025-02-13 | Hydrus Microstent | $65 |
| Bausch & Lomb Americas | Consulting · 2025-01-23 | None | $7,500 |
| Alcon Vision | Meals · 2025-01-21 | Constellation | $132 |
| Sight Sciences | Meals · 2025-01-21 | Omni Surgical System | $124 |
| Alcon Vision | Meals · 2025-01-20 | Hydrus Microstent | $150 |
| Thea Pharma | Meals · 2025-01-18 | Iyuzeh | $149 |
| Apellis Pharmaceuticals | Consulting · 2025-01-17 | Syfovre | $7,000 |
| Sight Sciences | Paid to speak or teach · 2025-01-16 | Omni Surgical System | $4,500 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $62,320
| Apellis Pharmaceuticals | Syfovre | $40,600 | 6 payments
|
| Sight Sciences | Omni Surgical System | $20,848 | 6 payments
|
| Alcon Vision | Hydrus Microstent | $726 | 8 payments
|
| Abbvie | Lumigan | $122 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Simplicity | $24 | 1 payment
|
2023: $237,803
| Apellis Pharmaceuticals | None | $152,250 | 14 payments
|
| Novartis Pharmaceuticals | None | $63,562 | 5 payments
|
| Sight Sciences | Omni Surgical System | $21,115 | 11 payments
|
| Alcon Vision | Hydrus Microstent | $547 | 7 payments
|
| AbbVie | Xen Glaucoma Treatment System | $121 | 1 payment
|
| Nova Eye | None | $66 | 1 payment
|
| Johnson & Johnson Vision Care | Tecnis Simplicity | $38 | 1 payment
|
| Oculus Surgical | None | $37 | 1 payment
|
| Bausch & Lomb Americas | Vyzulta | $34 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $33 | 1 payment
|
2022: $375,190
| Alcon Vision | Hydrus Microstent | $171,032 | 10 payments
|
| Apellis Pharmaceuticals | None | $79,293 | 10 payments
|
| Novartis Pharmaceuticals | None | $52,616 | 5 payments
|
| Glaukos | Istent Inject W | $30,353 | 5 payments
|
| Sight Sciences | Omni(R) Surgical System (US) | $21,201 | 19 payments
|
| Alcon Research | Hydrus Microstent | $20,224 | 11 payments
|
| Janssen Research & Development | Whitestar Phaco Handpiece | $285 | 2 payments
|
| Regeneron Pharmaceuticals | None | $141 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $43 | 1 payment
|
2021: $211,183
| Glaukos | Istent | $92,597 | 11 payments
|
| Novartis Pharmaceuticals | None | $44,811 | 3 payments
|
| Ivantis | Hydrus Microstent | $27,175 | 6 payments
|
| Allergan | None | $25,725 | 2 payments
|
| Sight Sciences | Omni(R) Surgical System (US) | $20,627 | 12 payments
|
| Ocular Therapeutix | Dextenza | $131 | 1 payment
|
| Alcon Vision | Acrysof Iq Panoptix | $117 | 1 payment
|
2020: $218,024
| Novartis Pharmaceuticals | None | $65,804 | 7 payments
|
| Glaukos | Istent Trabecular Micro-Bypass Stent System | $57,291 | 7 payments
|
| Alcon Research | Acrysof | $27,218 | 6 payments
|
| Ivantis | Hydrus | $25,625 | 4 payments
|
| Sight Sciences | Omni | $20,049 | 11 payments
|
| Ocular Therapeutix | Dextenza | $19,538 | 5 payments
|
| Allergan | None | $2,500 | 5 payments
|
2019: $251,677
| Glaukos | Istent Trabecular Micro-Bypass Stent System | $101,179 | 13 payments
|
| Novartis Pharmaceuticals | Beovu | $85,212 | 12 payments
|
| Alcon Research | Cypass | $23,085 | 10 payments
|
| Ivantis | Hydrus | $14,520 | 7 payments
|
| Allergan | Xen | $14,172 | 27 payments
|
| Sight Sciences | Omni | $9,638 | 4 payments
|
| Johnson & Johnson Surgical Vision | Ophthalmic Surgical Adjuncts | $3,438 | 4 payments
|
| Ocular Therapeutix | Resure Sealant | $224 | 3 payments
|
| Alcon Vision | Constellation | $211 | 5 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1093852253
- Licence
- CA A50924California A50924: Current · expires 2028-02-29
- Trained
- Johns Hopkins University School of Medicine, 1986
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 2680 Hanover St, Palo Alto, CA, 94304
- NPI first listed
- 2007-01-30
- NPI last updated
- 2024-03-21
- NPI record certified
- 2024-03-21
This is when the NPI record was last certified, not a medical board exam.